BRAF and cutaneous melanoma: The phase II study in patients with metastatic BRAF-mutant cutaneous melanoma, previously treated with BRAF or other types of inhibitors, reported an ORR of 25% and median PFS of 4 months in the group without previous BRAFi therapy.